Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) have been assigned an average recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $49.00.
AIMT has been the topic of several research analyst reports. Wedbush lowered their price target on Aimmune Therapeutics from $80.00 to $76.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 19th. Cantor Fitzgerald began coverage on Aimmune Therapeutics in a research report on Sunday, December 9th. They issued an “overweight” rating and a $23.75 price target on the stock. Credit Suisse Group reissued a “buy” rating and set a $40.00 target price on shares of Aimmune Therapeutics in a research report on Tuesday, January 15th. BidaskClub downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. Finally, Goldman Sachs Group began coverage on Aimmune Therapeutics in a research report on Thursday, December 13th. They set a “neutral” rating and a $32.00 target price on the stock.
Shares of NASDAQ:AIMT opened at $23.11 on Monday. The stock has a market capitalization of $1.44 billion, a PE ratio of -6.30 and a beta of -0.13. Aimmune Therapeutics has a 52-week low of $20.94 and a 52-week high of $36.12.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.